Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Abstract Background Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These agents induce systemic immunosuppression, with its associated morbidit...

Full description

Bibliographic Details
Main Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Dana Alsaadi, Joseph Jennings, Wenyi Luo, Zimu Gong, David M. Richards, Aline Charabaty, Yinghong Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Vedolizumab
Colitis
Diarrhea
Immunotherapy
Immune checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-018-0461-4

Internet

http://link.springer.com/article/10.1186/s40425-018-0461-4

Similar Items